Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

98.75CHF
31 Jul 2014
Price Change (% chg)

CHF-1.65 (-1.64%)
Prev Close
CHF100.40
Open
CHF100.90
Day's High
CHF100.90
Day's Low
CHF98.15
Volume
34,342
Avg. Vol
84,167
52-wk High
CHF129.80
52-wk Low
CHF66.30

BSLN.S

Chart for BSLN.S

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 2.11
Market Cap (Mil.): CHF1,034.71
Shares Outstanding (Mil.): 10.48
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 107.05 36.29
EPS (TTM): -3.40 -- --
ROI: -11.87 -0.60 18.13
ROE: -37.44 -1.65 18.95
Search Stocks

BRIEF-Basilea Pharmaceutica - enters into agreement with Quintiles for commercialization of Zevtera/Mabelio in Europe

July 21 - Basilea Pharmaceutica AG : * Says entered into agreement with Quintiles for commercialization of

21 Jul 2014

BRIEF- Basilea Pharmaceutica announces isavuconazole received QIDP designation from FDA

Isavuconazole as Qualified Infectious Disease Product (QIDP) for oral and intravenous treatment of invasive candidiasis Source text for Eikon: Further company coverage:

17 Jul 2014

BRIEF-Basilea Pharmaceutica submits Isavuconazole European marketing authorization application

July 17 - Basilea Pharmaceutica AG : * Submits Isavuconazole European marketing authorization application for the

17 Jul 2014

UPDATE 1-Basilea shares fall on setback for pneumonia drug in US

ZURICH, June 25 - Shares in Swiss biotech company Basilea fell by as much as 11.5 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.

25 Jun 2014

Basilea shares fall after setback for pneumonia treatment in US

ZURICH, June 25 - Shares in Swiss biotech company Basilea fell 8 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.

25 Jun 2014

BRIEF-Basilea Pharmaceutica gives update on ceftobiprole's U.S. regulatory status

June 25 - Basilea Pharmaceutica AG : * Says FDA confirmed that a potential regulatory approval of ceftobiprole in

25 Jun 2014

Basilea starts early-stage study with Gram-negative antibiotic

ZURICH, June 12 - Swiss biotech company Basilea said it had started an early-stage clinical study of an antibiotic to treat infections with multi-drug resistant Gram-negative bacteria in combination with another drug.

12 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks